2.11
+0.26(+14.05%)
Currency In USD
| Previous Close | 1.85 |
| Open | 1.9 |
| Day High | 2.15 |
| Day Low | 1.9 |
| 52-Week High | 3.36 |
| 52-Week Low | 0.86 |
| Volume | 441,796 |
| Average Volume | 329,934 |
| Market Cap | 127.81M |
| PE | -0.93 |
| EPS | -2.27 |
| Moving Average 50 Days | 1.6 |
| Moving Average 200 Days | 1.35 |
| Change | 0.26 |
If you invested $1000 in Acumen Pharmaceuticals, Inc. (ABOS) since IPO date, it would be worth $104.98 as of October 24, 2025 at a share price of $2.11. Whereas If you bought $1000 worth of Acumen Pharmaceuticals, Inc. (ABOS) shares 3 years ago, it would be worth $277.63 as of October 24, 2025 at a share price of $2.11.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
GlobeNewswire Inc.
Aug 05, 2025 8:00 PM GMT
NEWTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers fo
Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025
GlobeNewswire Inc.
Jul 28, 2025 12:00 PM GMT
NEWTON, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheime
Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
GlobeNewswire Inc.
Jul 15, 2025 11:00 AM GMT
Acumen and JCR aim to develop a product leveraging Acumen’s amyloid beta oligomer-selective antibody expertise and JCR’s transferrin-receptor-targeting blood-brain barrier-penetrating technologyPreclinical candidate data expected in early 2026, with